Pharmacokinetic properties of N-nitrosofenfluramine after its administration to rats
β Scribed by Amal Kaddoumi; Mitsuhiro Wada; Kenichiro Nakashima
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 895 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0269-3879
- DOI
- 10.1002/bmc.1485
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
NβNitrosofenfluramine (NβFen), a synthetic adulterant in Chinese herbal diet products, is believed to cause hepatotoxicity in people who use these products. NβFen is a relatively new compound, and thus pharmacological and toxicological studies are insufficient. The aim of this work was to (1) define NβFen's plasma pharmacokinetics and tissue distribution after single intraperitoneal (i.p.) administration of 25βmg/kg to rats; (2) define its bioavailability; and (3) identify fenfluramine (Fen) and norfenfluramine (Norf) as NβFen metabolites. NβFen rapidly appeared in the circulation and was distributed to all tissues. Norf was found to be the primary metabolite and not Fen. Plasma and tissue levels of NβFen and Norf were low with bioavailability of NβFen after i.p. administration was <3%. The AUC~0~~βt~ of NβFen in the liver and kidney were 6.6 and 12.1 times, respectively, greater than the brain, and 17.8 and 32.6 times, respectively, greater than the plasma. In conclusion, NβFen did not show local accumulation in the liver, the site of toxicity, with concentrations represented as percentage of the total dose ranginng from 0.008 to 0.122%; hence the cause of hepatotoxicity could be related to the mechanisms other than toxicity consequences accumulation. Copyright Β© 2010 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
Background: Artesunate is a commonly used antimalarial drug derived from artemisinin. It is rapidly converted to dihydroartemisinin. Little is known on this conversion in the GI tract and blood, and how this influences absorption. In order to study the absorption phase of the kinetics of artesunate
## Abstract The pharmacokinetics of desethylamiodarone (DEA), the active metabolite of amiodarone (AM), were studied in the rat after administration of AM or preformed metabolite. Rats received 10βmg/kg of either intravenous or oral AM HCl or DEA base. Blood samples were obtained via a surgically i
BMS-204352 is a novel maxi-K channel opener that is being developed for the treatment for stroke. The current study was designed to evaluate the dose proportionality and pharmacokinetics of BMS-204352 in rats. In an open, parallel fashion, sixteen rats per gender received a single intraarterial dose